Candidate molecular markers that have been associated with progression in IBD (described earlier in the review) including aneuploidy, methylation assays, microsatellite instability and mutational panels of key driver genes in IBD-CRC (such as TP53, APC, KRAS, and CDK2NA). The gene discussed is TP53; the disease is colorectal carcinoma.